Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) EPS (Basic) (2016 - 2025)

Lipocine's EPS (Basic) history spans 13 years, with the latest figure at -$0.59 for Q3 2025.

  • For Q3 2025, EPS (Basic) fell 43.9% year-over-year to -$0.59; the TTM value through Sep 2025 reached -$1.02, down 37.41%, while the annual FY2024 figure was -$0.0, 99.95% up from the prior year.
  • EPS (Basic) reached -$0.59 in Q3 2025 per LPCN's latest filing, down from -$0.41 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.66 in Q1 2024 to a low of -$1.96 in Q4 2022.
  • Average EPS (Basic) over 5 years is -$0.39, with a median of -$0.41 recorded in 2024.
  • Peak YoY movement for EPS (Basic): surged 333.33% in 2021, then plummeted 1750.0% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at $0.14 in 2021, then plummeted by 1500.0% to -$1.96 in 2022, then surged by 78.57% to -$0.42 in 2023, then soared by 179.32% to $0.33 in 2024, then plummeted by 277.11% to -$0.59 in 2025.
  • Per Business Quant, the three most recent readings for LPCN's EPS (Basic) are -$0.59 (Q3 2025), -$0.41 (Q2 2025), and -$0.35 (Q1 2025).